Characterization of a human monoclonal antibody to lipopolysaccharides of Pseudomonas aeruginosa serotype 5: a possible candidate as an immunotherapeutic agent for infections with P. aeruginosa.

A human monoclonal antibody, P3D9 (IgG2, lambda type), that bound to Pseudomonas aeruginosa Homma serotype 5 cells with high specificity was produced by cell fusion between a human tonsillar lymphocyte and a mouse plasmacytoma cell, P3-X63-Ag8-U1 (P3U1). The yield of P3D9 secreted into the culture supernatant from the mouse-human hybridoma was 2-10 micrograms/ml, and this hybridoma cell line has been stably producing this antibody for six months. Antibody P3D9 alone did not cause agglutination of serotype 5 cells, but the cells were agglutinated after addition of goat antibody to human IgG. Antibody P3D9 was proven to have protective activity against infection with P. aeruginosa, and the 50% protective dose estimated for experimental peritoneal infection with P. aeruginosa was 2.4 micrograms per mouse.

[1]  U. Hämmerling,et al.  A human monoclonal antibody to cytomegalovirus (CMV). , 1984, Journal of immunology.

[2]  Y. Masuho,et al.  Protection against infection with Pseudomonas aeruginosa by passive transfer of monoclonal antibodies to lipopolysaccharides and outer membrane proteins. , 1984, The Journal of infectious diseases.

[3]  R. Berg,et al.  Use of a purified outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine in mice , 1984, Infection and immunity.

[4]  S. Cryz,et al.  Protection against fatal Pseudomonas aeruginosa burn wound sepsis by immunization with lipopolysaccharide and high-molecular-weight polysaccharide , 1984, Infection and immunity.

[5]  R. Hancock,et al.  Surface localization of Pseudomonas aeruginosa outer membrane porin protein F by using monoclonal antibodies , 1983, Infection and immunity.

[6]  S. Cryz,et al.  Protection against Pseudomonas aeruginosa infection in a murine burn wound sepsis model by passive transfer of antitoxin A, antielastase, and antilipopolysaccharide , 1983, Infection and immunity.

[7]  M. J. Barlow,et al.  PRODUCTION OF HUMAN MONOCLONAL ANTIBODY TO RHESUS D ANTIGEN , 1983, The Lancet.

[8]  R. Insel,et al.  Protective human hybridoma antibody to tetanus toxin. , 1982, The Journal of clinical investigation.

[9]  J. Roder,et al.  Human hybridomas constructed with antigen-specific Epstein-Barr virus-transformed cell lines. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[10]  H. Koprowski,et al.  Production of human hybridomas secreting antibodies to measles virus , 1980, Nature.

[11]  H. Kaplan,et al.  Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[12]  H. Koprowski,et al.  Preferential retention of human chromosome 14 in mouse × human B cell hybrids , 1980 .

[13]  G. Pier,et al.  Protective immunity induced in mice by immunization with high-molecular-weight polysaccharide from Pseudomonas aeruginosa , 1978, Infection and immunity.

[14]  M. Fisher.  A polyvalent human gamma-globulin immune to Pseudomonas aeruginosa: passive protection of mice against lethal infection. , 1977, The Journal of infectious diseases.

[15]  B. Andersen,et al.  Passive immunity against pseudomonas sepsis during granulocytopenia , 1976, Infection and immunity.

[16]  M. Perry,et al.  Improved techniques for the preparation of bacterial lipopolysaccharides. , 1976, Canadian journal of microbiology.

[17]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[18]  G. Bertani,et al.  STUDIES ON LYSOGENESIS I , 1951, Journal of bacteriology.